세계의 분자진단 시장(-2030년) : 제품 및 서비스, 검사 유형, 샘플, 기술, 용도(감염증, 암)

The molecular diagnostics market is valued at an estimated USD 19.48 billion in 2025 and is projected to reach USD 30.74 billion by 2030 at a CAGR of 9.6% during the forecast period. Molecular diagnostics plays a vital role in modern healthcare by enabling disease detection at the molecular and genetic level. These technologies offer high sensitivity and specificity, allowing for the early identification of pathogens and genetic abnormalities. Continuous technological advancements, such as faster processing times, automated platforms, and improved assay designs, have significantly enhanced the reliability and accessibility of molecular tests. These innovations are significant in supporting large-scale testing efforts across diverse healthcare settings.

Moreover, in countries like India, government and private sector initiatives contribute to increased public awareness and greater access to diagnostic and treatment services. Such efforts are expected to accelerate the adoption of molecular diagnostics in the coming years.

"By sample type, the blood, serum, and plasma segment dominated the molecular diagnostics market in 2024."

By sample type, the molecular diagnostics market is segmented into blood, serum & plasma; urine; and other sample types. The blood, serum, and plasma segment accounted for the largest share of the market in 2024. This is attributed to the high sensitivity and specificity these sample types offer in detecting a wide range of diseases, including viral infections and oncological conditions. Their stability during transportation and storage makes them ideal for centralized laboratories and point-of-care settings. Additionally, the growing adoption of personalized medicine and increased use of biomarkers in clinical decision-making fuel the demand for blood-based molecular testing. These advantages collectively position the segment for continued strong growth.

"By technology, the DNA sequencing & next-generation sequencing (NGS) segment is projected to achieve the highest growth during the forecast period."

By technology, the molecular diagnostics market is bifurcated into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies. The DNA sequencing & next-generation sequencing (NGS) segment is projected to witness the highest growth during the forecast period. This surge is driven by their expanding use in detecting genetic mutations, identifying infectious agents, and guiding personalized treatment plans. The increasing turnaround time and data accuracy improvements have also broadened their adoption in research and clinical settings. Moreover, NGS is gaining traction due to its high-throughput capabilities and utility in comprehensive genomic profiling. As precision medicine continues to advance, the demand for sequencing-based diagnostics is set to rise significantly.

"Asia Pacific is projected to be the fastest-growing regional market during the forecast period."

The market for molecular diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to witness the highest growth in the global molecular diagnostics market during the forecast period. This growth is supported by the rising healthcare investments, growing awareness of early disease detection, and increasing adoption of advanced diagnostic technologies across emerging economies. Countries such as China, India, and South Korea are experiencing rapid improvements in healthcare infrastructure and laboratory capacity. In addition, government initiatives aimed at strengthening infectious disease surveillance and expanding access to molecular testing are contributing to market growth. The large patient population and rising demand for personalized healthcare solutions further reinforce the region's growth potential.

Break-up of primary participant profiles in the molecular diagnostics market:

• By Company Type: Tier 1 - 40%, Tier 2 -30%, and Tier 3 - 30%
• By Designation: C-level - 27%, Director-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa - 4%

The key players in the molecular diagnostics market are Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Illumina, Inc. (US), Abbott Laboratories (US), bioMerieux (France), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity, Inc. (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), Agilent Technologies, Inc. (US), MDxHealth (Belgium), Biocartis (Belgium), Bruker (US), TBG Diagnostics Limited (Australia), Amoy Diagnostics Co., Ltd. (China), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), geneOmbio Technologies (India), Savyon Diagnostics (Israel), and Uniogen OY (Finland).

Research Coverage:

This research report categorizes the molecular diagnostics market by product & service (reagents & kits, instruments, and services), test type (lab tests and PoC tests), sample type (blood, serum & plasma; urine; and other sample types), technology (polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies), application {infectious disease diagnostics [hepatitis (hepatitis B, hepatitis C & other hepatitis diseases), sexually transmitted diseases (HIV, CT/NG, HPV, syphilis, & other sexually transmitted diseases), respiratory infectious diseases (tuberculosis, influenza, pharyngitis, & other respiratory infectious diseases), hospital-acquired infections, vector-borne diseases, and other infectious diseases], oncology testing (breast cancer, colorectal cancer, lung cancer, prostate cancer, and other cancers), genetic testing and other applications}, technique (multiplex testing and singleplex testing), clinical application (diagnostic and screening), end user (hospitals & clinics, diagnostic laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the molecular diagnostics market. A thorough analysis of the key industry players provides insights into their business overview, solutions, key strategies, acquisitions, and agreements. This report also covers a competitive analysis of upcoming startups in the molecular diagnostics market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall molecular diagnostics market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report will help stakeholders understand the market pulse, providing information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers [Increasing prevalence of infectious diseases and cancer, growing R&D funding, surge in technological advancements in molecular diagnostics, and rising use of point-of-care (PoC) diagnostic tests], opportunities (Growing significance of companion diagnostics and increasing growth opportunities in emerging economies), restraints (Inadequate reimbursements and high cost of molecular diagnostic instruments), and challenges (Changing regulatory landscape, operational barriers and labor shortage, and introduction of alternative technologies) influencing the growth of the molecular diagnostics market.
• Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and new product launches in the molecular diagnostics market
• Market Development: Comprehensive information about lucrative markets across varied regions
• Market Diversification: Exhaustive information about products, untapped geographies, recent developments, and investments in the molecular diagnostics market
• Competitive Assessment: In-depth assessment of market share, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), bioMerieux (France), and Hologic, Inc. (US)

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION
  • 1.3.2 REGIONAL SCOPE
• 1.4 INCLUSIONS & EXCLUSIONS
• 1.5 YEARS CONSIDERED
• 1.6 CURRENCY CONSIDERED
• 1.7 KEY STAKEHOLDERS
• 1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Presentation of companies and primary interviews
    • 2.2.1.3 Growth forecast
    • 2.2.1.4 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ASSESSMENT
• 2.5 RESEARCH ASSUMPTIONS
  • 2.5.1 PARAMETRIC ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
• 4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030
• 4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030
• 4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030
• 4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030
• 4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030
• 4.7 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2025 VS. 2030
• 4.8 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030
• 4.9 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030
• 4.10 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of infectious diseases and cancer
    • 5.2.1.2 Growing R&D funding
    • 5.2.1.3 Surge in technological advancements
    • 5.2.1.4 Rising use of point-of-care diagnostic tests
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Inadequate reimbursements
    • 5.2.2.2 High cost of molecular diagnostic instruments
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing significance of companion diagnostics
    • 5.2.3.2 Increasing growth opportunities in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Changing regulatory landscape
    • 5.2.4.2 Operational barriers and labor shortage
    • 5.2.4.3 Introduction of alternative technologies
• 5.3 PRICING ANALYSIS
  • 5.3.1 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS
  • 5.3.2 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC REAGENTS & KITS, BY KEY PLAYER
  • 5.3.3 AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 HS CODES
  • 5.7.1 IMPORT SCENARIO (HS CODE 3822)
  • 5.7.2 EXPORT SCENARIO (HS CODE 3822)
• 5.8 ECOSYSTEM ANALYSIS
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT FROM NEW ENTRANTS
  • 5.9.2 THREAT FROM SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY FRAMEWORK
    • 5.10.1.1 North America
      • 5.10.1.1.1 US
      • 5.10.1.1.2 Canada
    • 5.10.1.2 Europe
      • 5.10.1.2.1 Germany
      • 5.10.1.2.2 UK
      • 5.10.1.2.3 France
      • 5.10.1.2.4 Italy
    • 5.10.1.3 Asia Pacific
      • 5.10.1.3.1 China
      • 5.10.1.3.2 Japan
      • 5.10.1.3.3 India
    • 5.10.1.4 Latin America
      • 5.10.1.4.1 Brazil
      • 5.10.1.4.2 Mexico
    • 5.10.1.5 Middle East
      • 5.10.1.5.1 Africa
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Polymerase chain reaction
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Microarrays
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Next-generation sequencing
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT AND FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION
  • 5.16.2 CASE STUDY 2: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS AND BED MANAGEMENT
  • 5.16.3 CASE STUDY 3: RAPID PCR TESTING STREAMLINED EMERGENCY CARE AND SURGICAL RESOURCE MANAGEMENT IN GERMAN HOSPITAL
• 5.17 IMPACT OF AI/GENERATIVE AI ON MOLECULAR DIAGNOSTICS MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI
    • 5.17.2.1 Key use cases
  • 5.17.3 IMPLEMENTATION OF AI BY KEY COMPANIES
  • 5.17.4 FUTURE OF AI IN MOLECULAR DIAGNOSTICS MARKET
• 5.18 US 2025 TARIFF
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Hospitals & clinics
    • 5.18.5.2 Diagnostic laboratories

6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 REAGENTS & KITS
  • 6.2.1 INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION TO PROPEL MARKET
• 6.3 INSTRUMENTS
  • 6.3.1 RISING NEED FOR QUICK AND ACCURATE TEST RESULTS TO BOOST MARKET
• 6.4 SERVICES & SOFTWARE
  • 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE MARKET

7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE

• 7.1 INTRODUCTION
• 7.2 LAB TESTS
  • 7.2.1 INCREASING NEED FOR AUTOMATION AND EFFICIENT DISEASE TESTING TO DRIVE MARKET
• 7.3 POC TESTS
  • 7.3.1 INCREASED INVESTMENT BY PUBLIC HEALTH AGENCIES AND GOVERNMENTS TO BOOST MARKET

8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

• 8.1 INTRODUCTION
• 8.2 BLOOD, SERUM, AND PLASMA
  • 8.2.1 INCREASING UTILIZATION IN GENETIC TESTING, INFECTIOUS DISEASE DIAGNOSIS, AND CANCER DIAGNOSTICS TO PROPEL MARKET
• 8.3 URINE
  • 8.3.1 NEED FOR NON-INVASIVE AND EASY SAMPLE COLLECTION TECHNIQUE TO FUEL MARKET
• 8.4 OTHER SAMPLE TYPES

9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
• 9.2 POLYMERASE CHAIN REACTION
  • 9.2.1 RISING USE IN PROTEOMICS AND GENOMICS TO AID GROWTH
• 9.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
  • 9.3.1 NEED FOR PROMPT DIAGNOSIS TO STIMULATE GROWTH
• 9.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
  • 9.4.1 GROWING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
• 9.5 IN SITU HYBRIDIZATION
  • 9.5.1 RISING APPLICATIONS IN DIAGNOSING CHROMOSOMAL ABNORMALITIES AND GENE MAPPING TO BOOST MARKET
• 9.6 DNA MICROARRAYS
  • 9.6.1 SURGE IN ADVANCEMENTS IN DESIGN, DENSITY, AND DETECTION TECHNIQUES TO FUEL MARKET
• 9.7 OTHER TECHNOLOGIES

10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 INFECTIOUS DISEASE DIAGNOSTICS
  • 10.2.1 SEXUALLY TRANSMITTED DISEASES
    • 10.2.1.1 CT/NG
      • 10.2.1.1.1 Growing development of novel assays to boost market
    • 10.2.1.2 HIV
      • 10.2.1.2.1 Increasing blood transfusions and blood donations to propel market
    • 10.2.1.3 HPV
      • 10.2.1.3.1 Rising cases of cervical cancer to augment growth
    • 10.2.1.4 Syphilis
      • 10.2.1.4.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market
    • 10.2.1.5 Other sexually transmitted diseases
  • 10.2.2 HEPATITIS
    • 10.2.2.1 Hepatitis B
      • 10.2.2.1.1 Need for ongoing management and monitoring of virus to drive market
    • 10.2.2.2 Hepatitis C
      • 10.2.2.2.1 Favorable government initiatives to support growth
    • 10.2.2.3 Other hepatitis diseases
  • 10.2.3 RESPIRATORY INFECTIOUS DISEASES
    • 10.2.3.1 Tuberculosis
      • 10.2.3.1.1 Rising focus on reducing tuberculosis deaths to fuel market
    • 10.2.3.2 Influenza
      • 10.2.3.2.1 Growing strains and subtypes to drive market
    • 10.2.3.3 Pharyngitis
      • 10.2.3.3.1 Need to differentiate between bacterial and viral infections to fuel growth
    • 10.2.3.4 Other respiratory infectious diseases
  • 10.2.4 HOSPITAL-ACQUIRED INFECTIONS
    • 10.2.4.1 Booming geriatric population to aid growth
  • 10.2.5 VECTOR-BORNE DISEASES
    • 10.2.5.1 Growing focus on disease surveillance to propel market
  • 10.2.6 OTHER INFECTIOUS DISEASES
• 10.3 ONCOLOGY TESTING
  • 10.3.1 BREAST CANCER
    • 10.3.1.1 Increasing need to improve survival rates to support growth
  • 10.3.2 COLORECTAL CANCER
    • 10.3.2.1 Rising demand for biomarkers to fuel market
  • 10.3.3 LUNG CANCER
    • 10.3.3.1 Increasing use of predictive biomarkers to drive market
  • 10.3.4 PROSTATE CANCER
    • 10.3.4.1 Surge in advancements in genomic technologies to aid growth
  • 10.3.5 OTHER CANCER TYPES
• 10.4 GENETIC TESTING
  • 10.4.1 GROWING IMPORTANCE OF DIAGNOSING AND MANAGING RARE GENETIC DISEASES TO PROPEL MARKET
• 10.5 OTHER APPLICATIONS

11 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

• 11.1 INTRODUCTION
• 11.2 MULTIPLEX TESTING
  • 11.2.1 RISING DEMAND FOR QUICK DIAGNOSIS TO PROMOTE GROWTH
• 11.3 SINGLEPLEX TESTING
  • 11.3.1 NEED FOR AFFORDABLE TESTING TO AUGMENT GROWTH

12 MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION

• 12.1 INTRODUCTION
• 12.2 DIAGNOSTIC
  • 12.2.1 INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING AND TIMELY TREATMENT TO DRIVE MARKET
• 12.3 SCREENING
  • 12.3.1 GROWING IMPORTANCE OF EARLY INFECTIOUS DISEASE SCREENING TO PROPEL MARKET EXPANSION

13 MOLECULAR DIAGNOSTICS MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 DIAGNOSTIC LABORATORIES
  • 13.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR COST REDUCTION TO AID GROWTH
• 13.3 HOSPITALS & CLINICS
  • 13.3.1 GROWING FOCUS ON HEALTHCARE SYSTEMS TO STIMULATE GROWTH
• 13.4 OTHER END USERS

14 MOLECULAR DIAGNOSTICS MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 MACROECONOMIC OUTLOOK
  • 14.2.2 US
    • 14.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditures to drive market
  • 14.2.3 CANADA
    • 14.2.3.1 Growing focus on genomic research to fuel market
• 14.3 EUROPE
  • 14.3.1 MACROECONOMIC OUTLOOK
  • 14.3.2 GERMANY
    • 14.3.2.1 Robust healthcare spending and increasing per capita disposable income to propel market
  • 14.3.3 UK
    • 14.3.3.1 Expanding community-based diagnostics to drive adoption of molecular diagnostics
  • 14.3.4 FRANCE
    • 14.3.4.1 Rising R&D expenditure for product launches and development of new technologies to augment growth
  • 14.3.5 ITALY
    • 14.3.5.1 Growing demographic shift toward elderly population to support market
  • 14.3.6 SPAIN
    • 14.3.6.1 Surge in demand for genetic and prenatal testing to aid growth
  • 14.3.7 RUSSIA
    • 14.3.7.1 Increasing access to quality healthcare to boost market growth
  • 14.3.8 SWITZERLAND
    • 14.3.8.1 Rising healthcare spending for new medications and therapies to drive market
  • 14.3.9 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 MACROECONOMIC OUTLOOK
  • 14.4.2 CHINA
    • 14.4.2.1 Growing public access to modern healthcare to drive market
  • 14.4.3 JAPAN
    • 14.4.3.1 Universal healthcare reimbursement policy to support market
  • 14.4.4 INDIA
    • 14.4.4.1 Increasing penetration of medical insurance, hospital setups, and foreign direct investments to fuel market
  • 14.4.5 AUSTRALIA
    • 14.4.5.1 Rising technological advancements to stimulate growth
  • 14.4.6 SOUTH KOREA
    • 14.4.6.1 Favorable government initiatives for promoting medical tourism to support growth
  • 14.4.7 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 MACROECONOMIC OUTLOOK
  • 14.5.2 BRAZIL
    • 14.5.2.1 Universal healthcare access to drive adoption in Brazil
  • 14.5.3 MEXICO
    • 14.5.3.1 Booming medical tourism industry to aid growth
  • 14.5.4 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST & AFRICA
  • 14.6.1 MACROECONOMIC OUTLOOK
  • 14.6.2 SAUDI ARABIA
    • 14.6.2.1 Rising government healthcare expenditure to boost market
  • 14.6.3 UAE
    • 14.6.3.1 Improvements in healthcare infrastructure to support growth
  • 14.6.4 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
• 15.3 REVENUE SHARE ANALYSIS
• 15.4 MARKET SHARE ANALYSIS, 2024
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Product & service footprint
    • 15.5.5.4 Sample type footprint
    • 15.5.5.5 Application footprint
• 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 RESPONSIVE COMPANIES
  • 15.6.3 DYNAMIC COMPANIES
  • 15.6.4 STARTING BLOCKS
  • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 15.6.5.1 Detailed list of key startups/SMES
    • 15.6.5.2 Competitive benchmarking of startups/SMES
• 15.7 COMPANY VALUATION & FINANCIAL METRICS
  • 15.7.1 FINANCIAL METRICS
  • 15.7.2 COMPANY VALUATION
• 15.8 BRAND/PRODUCT COMPARISON
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 PRODUCT/SERVICES LAUNCHES AND APPROVALS
  • 15.9.2 DEALS
  • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 DANAHER CORPORATION
    • 16.1.1.1 Business overview
    • 16.1.1.2 Products/Services offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Product/Service launches and approvals
      • 16.1.1.3.2 Deals
      • 16.1.1.3.3 Expansions
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Right to win
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses and competitive threats
  • 16.1.2 F. HOFFMANN-LA ROCHE LTD
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products/Services offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Product/Service launches and approvals
      • 16.1.2.3.2 Deals
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Right to win
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses and competitive threats
  • 16.1.3 ILLUMINA, INC.
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products/Services offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Product/Service launches and approvals
      • 16.1.3.3.2 Deals
      • 16.1.3.3.3 Expansions
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Right to win
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses and competitive threats
  • 16.1.4 HOLOGIC, INC.
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products/Services offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Product/Service launches and approvals
      • 16.1.4.3.2 Deals
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Right to win
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses and competitive threats
  • 16.1.5 BIOMERIEUX
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products/Services offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Product/Service launches and approvals
      • 16.1.5.3.2 Deals
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Right to win
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses and competitive threats
  • 16.1.6 ABBOTT LABORATORIES
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products/Services offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Product/Service launches and approvals
      • 16.1.6.3.2 Deals
  • 16.1.7 THERMO FISHER SCIENTIFIC INC.
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products/Services offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Product/Service launches and approvals
      • 16.1.7.3.2 Deals
  • 16.1.8 QIAGEN N.V.
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products/Services offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Product/Service launches and approvals
      • 16.1.8.3.2 Deals
      • 16.1.8.3.3 Expansions
  • 16.1.9 REVVITY, INC.
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products/Services offered
  • 16.1.10 MYRIAD GENETICS, INC.
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products/Services offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Product/Service launches and approvals
      • 16.1.10.3.2 Deals
  • 16.1.11 SIEMENS HEALTHINEERS AG
    • 16.1.11.1 Business overview
    • 16.1.11.2 Products/Services offered
    • 16.1.11.3 Recent developments
      • 16.1.11.3.1 Product/Service launches and approvals
      • 16.1.11.3.2 Deals
      • 16.1.11.3.3 Expansions
• 16.2 OTHER PLAYERS
  • 16.2.1 BECTON, DICKINSON AND COMPANY (BD)
  • 16.2.2 GRIFOLS, S.A.
  • 16.2.3 QUIDELORTHO CORPORATION
  • 16.2.4 DIASORIN S.P.A.
  • 16.2.5 EXACT SCIENCES CORPORATION
  • 16.2.6 GENETIC SIGNATURES
  • 16.2.7 AGILENT TECHNOLOGIES, INC.
  • 16.2.8 MDXHEALTH
  • 16.2.9 BIOCARTIS
  • 16.2.10 MEDIGEN BIOTECHNOLOGY CORP.
  • 16.2.11 VELA DIAGNOSTICS
  • 16.2.12 AMOY DIAGNOSTICS CO., LTD.
  • 16.2.13 BRUKER CORPORATION (ELITECHGROUP)
  • 16.2.14 MOLBIO DIAGNOSTICS LIMITED
  • 16.2.15 GENEOMBIOTECHNOLOGIES
  • 16.2.16 SAVYON DIAGNOSTICS
  • 16.2.17 UNIOGEN OY

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS